{"hands_on_practices": [{"introduction": "The first step in any gene therapy strategy is designing the vector that will carry the therapeutic genetic payload. While we often focus on the biological function of promoters and coding sequences, a critical and unyielding constraint is the physical size of the vector. This exercise [@problem_id:4676317] provides hands-on practice with a fundamental calculation in AAV vectorology: determining the maximum cargo capacity by accounting for the size of all necessary genetic components, a crucial step that dictates which genes are even eligible for AAV-mediated therapy.", "problem": "You are designing a retinal gene augmentation vector using Adeno-associated virus (AAV) for a loss-of-function inherited retinal disorder. The AAV genome that is packaged is defined from inverted terminal repeat (ITR) to ITR. Adopt the following foundational principles: the Central Dogma of molecular biology implies that a coding sequence must be fully contained in the vector to be expressed; and, for AAV vectors, efficient packaging requires that the total nucleotide content from ITR to ITR does not exceed the packaging limit. Assume linear additivity of sequence lengths across all vector components and ignore any non-sequence packaging overhead.\n\nThe vector components are: a promoter of length $0.5$ kb, a coding sequence of unknown length $L_{\\mathrm{cds}}$ kb, a polyadenylation signal (polyA) of length $0.2$ kb, and two inverted terminal repeats (ITRs) of length $0.29$ kb each. The AAV packaging limit is $4.7$ kb.\n\nUsing only these principles and data, determine the maximum allowable coding sequence length $L_{\\mathrm{cds}}$ (in kilobases) such that the total packaged genome length does not exceed the limit. Then, briefly explain in words how inclusion of additional regulatory elements (for example, introns, enhancers, or post-transcriptional elements) of total length $r$ kb would alter this maximum.\n\nExpress your final numerical answer for the maximum allowable coding sequence length in kilobases (kb), rounded to three significant figures.", "solution": "The problem is deemed valid as it is scientifically grounded in the principles of molecular biology and viral vector design, is well-posed with sufficient and consistent data, and is formulated objectively.\n\nThe problem requires the determination of the maximum allowable length for a coding sequence ($L_{\\mathrm{cds}}$) to be packaged within an Adeno-associated virus (AAV) vector, given constraints on the total genome size.\n\nFirst, we define the total length of the single-stranded DNA genome to be packaged, denoted as $L_{\\mathrm{total}}$. The problem states this genome is defined from Inverted Terminal Repeat (ITR) to ITR. In standard AAV vector biology, this refers to the entire nucleic acid molecule that is encapsulated, which includes both ITRs and all sequences situated between them. The problem specifies that we assume linear additivity of the lengths of all vector components. The components are the promoter, the coding sequence (CDS), the polyadenylation signal (polyA), and two ITRs.\n\nThe total length is therefore the sum of the lengths of these individual components:\n$$L_{\\mathrm{total}} = L_{\\mathrm{promoter}} + L_{\\mathrm{cds}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}}$$\n\nThe givens are:\n-   Promoter length, $L_{\\mathrm{promoter}} = 0.5$ kb\n-   Polyadenylation signal length, $L_{\\mathrm{polyA}} = 0.2$ kb\n-   Inverted terminal repeat length, $L_{\\mathrm{ITR}} = 0.29$ kb\n-   The AAV packaging limit, $L_{\\mathrm{limit}} = 4.7$ kb\n\nThe fundamental constraint is that the total length of the packaged genome cannot exceed the packaging limit:\n$$L_{\\mathrm{total}} \\le L_{\\mathrm{limit}}$$\n\nSubstituting the expression for $L_{\\mathrm{total}}$ into the inequality, we get:\n$$L_{\\mathrm{promoter}} + L_{\\mathrm{cds}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}} \\le L_{\\mathrm{limit}}$$\n\nTo find the maximum allowable coding sequence length, which we will denote as $L_{\\mathrm{cds, max}}$, we consider the case where the total length is exactly equal to the packaging limit. We can then rearrange the inequality to solve for $L_{\\mathrm{cds}}$:\n$$L_{\\mathrm{cds}} \\le L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}$$\nThus, the maximum length is:\n$$L_{\\mathrm{cds, max}} = L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}$$\n\nNow, we substitute the given numerical values into this equation. All lengths are in kilobases (kb).\n$$L_{\\mathrm{cds, max}} = 4.7 - 0.5 - 0.2 - 2 \\times (0.29)$$\nFirst, we calculate the total length contributed by the two ITRs:\n$$2 \\times 0.29 = 0.58 \\text{ kb}$$\nNow, substitute this back into the equation for $L_{\\mathrm{cds, max}}$:\n$$L_{\\mathrm{cds, max}} = 4.7 - 0.5 - 0.2 - 0.58$$\nSumming the lengths of the non-CDS components:\n$$0.5 + 0.2 + 0.58 = 1.28 \\text{ kb}$$\nFinally, subtracting this sum from the packaging limit:\n$$L_{\\mathrm{cds, max}} = 4.7 - 1.28 = 3.42 \\text{ kb}$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value of $3.42$ already has three significant figures.\n\nFor the second part of the question, we are asked to explain how the inclusion of additional regulatory elements of total length $r$ kb would alter this maximum. According to the principle of linear additivity of sequence lengths, these additional elements would occupy space within the packaged genome. The total length of all non-CDS components would increase by $r$. The new equation for the maximum CDS length, let's call it $L'_{\\mathrm{cds, max}}$, would be:\n$$L'_{\\mathrm{cds, max}} = L_{\\mathrm{limit}} - (L_{\\mathrm{promoter}} + L_{\\mathrm{polyA}} + 2 \\times L_{\\mathrm{ITR}} + r)$$\nThis can be expressed in terms of the original maximum length:\n$$L'_{\\mathrm{cds, max}} = (L_{\\mathrm{limit}} - L_{\\mathrm{promoter}} - L_{\\mathrm{polyA}} - 2 \\times L_{\\mathrm{ITR}}) - r = L_{\\mathrm{cds, max}} - r$$\nTherefore, including additional regulatory elements of total length $r$ kb would directly reduce the maximum allowable coding sequence length by an amount equal to $r$. Each kilobase of sequence added for regulatory purposes must be subtracted from the available capacity for the coding sequence, as the total packaging limit is a strict physical constraint of the AAV capsid.", "answer": "$$\\boxed{3.42}$$", "id": "4676317"}, {"introduction": "Once a vector is designed, it must be delivered effectively to the target cells in the retina. The choice of delivery route is one of the most critical decisions in ophthalmic gene therapy, with profound implications for safety and efficacy. This problem [@problem_id:4676270] challenges you to quantify the impact of this choice by comparing the required vector concentrations for subretinal and intravitreal injections, demonstrating how biological barriers and clearance mechanisms can alter dosing requirements by orders of magnitude.", "problem": "A gene therapy program for inherited retinal disease defines dose using the metric of vector genomes per eye, specifically the number of transduction-competent vector genomes that reach photoreceptor nuclei. Let the target be $V_{\\mathrm{target}} = 1.2 \\times 10^{11}$ such genomes reaching photoreceptors per eye. Consider two clinically relevant ophthalmic delivery routes: subretinal and intravitreal injections.\n\nFor a subretinal injection, a delivered volume of $0.10 \\ \\mathrm{mL}$ is placed into the subretinal space as a localized bleb. Of the vector genomes that enter the bleb, a fraction $0.90$ is retained locally without reflux into the vitreous. Of the genomes retained in the subretinal space, a fraction $0.60$ ultimately achieves nuclear entry and productive expression in photoreceptors.\n\nFor an intravitreal injection, a delivered volume of $0.050 \\ \\mathrm{mL}$ is injected into the vitreous. Of the genomes present in the vitreous, a fraction $0.030$ crosses the inner limiting membrane to access the outer retina within a time window of $t = 1.0 \\ \\mathrm{day}$. While in the vitreous during this window, vector genomes are cleared or inactivated by first-order kinetics with a half-life of $t_{1/2} = 2.0 \\ \\mathrm{days}$. Of the genomes that arrive at the retina and remain viable at that time, a fraction $0.40$ achieves nuclear entry and productive expression in photoreceptors.\n\nAssume well-mixed solutions and that the loaded syringe concentration is homogeneous. Define the loading concentration $C$ as vector genomes per $\\mathrm{mL}$. Under the constraints above and using conservation of mass and first-order decay, the required loading concentrations $C_{\\mathrm{SR}}$ and $C_{\\mathrm{IV}}$ for subretinal and intravitreal administration, respectively, can be related to $V_{\\mathrm{target}}$, the delivered volume, and the route-specific effective delivery fractions.\n\nCompute the ratio $R = C_{\\mathrm{IV}} / C_{\\mathrm{SR}}$ of the required intravitreal to subretinal loading concentrations needed to achieve the same $V_{\\mathrm{target}}$. Round your answer to three significant figures. Express the ratio as a pure number without units.", "solution": "The problem has been validated and is determined to be scientifically grounded, well-posed, and objective. It contains a complete and consistent set of givens, allowing for a unique solution.\n\nThe objective is to compute the ratio $R = C_{\\mathrm{IV}} / C_{\\mathrm{SR}}$, where $C_{\\mathrm{IV}}$ and $C_{\\mathrm{SR}}$ are the required loading concentrations (in vector genomes per $\\mathrm{mL}$) for intravitreal and subretinal administration, respectively, to achieve a target number of transduced photoreceptor nuclei, $V_{\\mathrm{target}}$.\n\nFirst, let us analyze the subretinal (SR) delivery route. The loading concentration is $C_{\\mathrm{SR}}$, and the delivered volume is $V_{\\mathrm{del, SR}} = 0.10 \\ \\mathrm{mL}$. The total number of vector genomes injected is the product of the concentration and volume:\n$$N_{\\mathrm{inj, SR}} = C_{\\mathrm{SR}} \\times V_{\\mathrm{del, SR}}$$\nA fraction $f_{\\mathrm{retain, SR}} = 0.90$ of these genomes is retained in the subretinal space. The number of retained genomes is:\n$$N_{\\mathrm{retained, SR}} = N_{\\mathrm{inj, SR}} \\times f_{\\mathrm{retain, SR}} = (C_{\\mathrm{SR}} \\times V_{\\mathrm{del, SR}}) \\times f_{\\mathrm{retain, SR}}$$\nOf these retained genomes, a fraction $f_{\\mathrm{entry, SR}} = 0.60$ achieves nuclear entry in photoreceptors. This final number must equal the target, $V_{\\mathrm{target}}$.\n$$V_{\\mathrm{target}} = N_{\\mathrm{retained, SR}} \\times f_{\\mathrm{entry, SR}} = (C_{\\mathrm{SR}} \\times V_{\\mathrm{del, SR}}) \\times f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}}$$\nSolving for the required subretinal concentration, $C_{\\mathrm{SR}}$:\n$$C_{\\mathrm{SR}} = \\frac{V_{\\mathrm{target}}}{V_{\\mathrm{del, SR}} \\times f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}}}$$\n\nNext, we analyze the intravitreal (IV) delivery route. The loading concentration is $C_{\\mathrm{IV}}$, and the delivered volume is $V_{\\mathrm{del, IV}} = 0.050 \\ \\mathrm{mL}$. The total number of vector genomes injected is:\n$$N_{\\mathrm{inj, IV}} = C_{\\mathrm{IV}} \\times V_{\\mathrm{del, IV}}$$\nThese genomes are subject to first-order clearance while in the vitreous. The number of genomes $N(t)$ remaining at time $t$ is given by $N(t) = N_0 \\exp(-kt)$, where $k$ is the rate constant and $N_0$ is the initial number. The rate constant $k$ is related to the half-life $t_{1/2}$ by $k = \\frac{\\ln(2)}{t_{1/2}}$.\nGiven $t_{1/2} = 2.0 \\ \\mathrm{days}$ and the relevant time window is $t = 1.0 \\ \\mathrm{day}$, the decay term $kt$ is:\n$$kt = \\frac{\\ln(2)}{2.0 \\ \\mathrm{days}} \\times 1.0 \\ \\mathrm{day} = \\frac{\\ln(2)}{2}$$\nThe fraction of genomes remaining viable after this time is $\\exp(-kt)$:\n$$\\exp(-kt) = \\exp\\left(-\\frac{\\ln(2)}{2}\\right) = \\exp\\left(\\ln\\left(2^{-1/2}\\right)\\right) = 2^{-1/2} = \\frac{1}{\\sqrt{2}}$$\nThe process to reach the target photoreceptors involves several steps. A fraction $f_{\\mathrm{access, IV}} = 0.030$ of the injected genomes accesses the outer retina, a process that occurs over time $t$ during which clearance happens. Of those that arrive viably, a fraction $f_{\\mathrm{entry, IV}} = 0.40$ achieves nuclear entry. Thus, the effective delivery is a product of these efficiencies, including the viability loss due to clearance.\n$$V_{\\mathrm{target}} = (N_{\\mathrm{inj, IV}}) \\times f_{\\mathrm{access, IV}} \\times \\exp(-kt) \\times f_{\\mathrm{entry, IV}}$$\nSubstituting the expression for $N_{\\mathrm{inj, IV}}$:\n$$V_{\\mathrm{target}} = (C_{\\mathrm{IV}} \\times V_{\\mathrm{del, IV}}) \\times f_{\\mathrm{access, IV}} \\times \\exp(-kt) \\times f_{\\mathrm{entry, IV}}$$\nSolving for the required intravitreal concentration, $C_{\\mathrm{IV}}$:\n$$C_{\\mathrm{IV}} = \\frac{V_{\\mathrm{target}}}{V_{\\mathrm{del, IV}} \\times f_{\\mathrm{access, IV}} \\times \\exp(-kt) \\times f_{\\mathrm{entry, IV}}}$$\n\nNow we can compute the ratio $R = C_{\\mathrm{IV}} / C_{\\mathrm{SR}}$.\n$$R = \\frac{C_{\\mathrm{IV}}}{C_{\\mathrm{SR}}} = \\frac{\\frac{V_{\\mathrm{target}}}{V_{\\mathrm{del, IV}} \\times f_{\\mathrm{access, IV}} \\times \\exp(-kt) \\times f_{\\mathrm{entry, IV}}}}{\\frac{V_{\\mathrm{target}}}{V_{\\mathrm{del, SR}} \\times f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}}}}$$\nThe term $V_{\\mathrm{target}}$ cancels out, yielding:\n$$R = \\frac{V_{\\mathrm{del, SR}} \\times f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}}}{V_{\\mathrm{del, IV}} \\times f_{\\mathrm{access, IV}} \\times f_{\\mathrm{entry, IV}} \\times \\exp(-kt)}$$\nWe can define the overall effective delivery fraction for each route, $\\eta$, which represents the fraction of the injected dose (per unit volume) that successfully reaches the target.\n$$\\eta_{\\mathrm{SR}} = f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}}$$\n$$\\eta_{\\mathrm{IV}} = f_{\\mathrm{access, IV}} \\times f_{\\mathrm{entry, IV}} \\times \\exp(-kt)$$\nThen the ratio is $R = \\frac{V_{\\mathrm{del, SR}} \\times \\eta_{\\mathrm{SR}}}{V_{\\mathrm{del, IV}} \\times \\eta_{\\mathrm{IV}}}$.\nLet's substitute the given numerical values:\n- $V_{\\mathrm{del, SR}} = 0.10$\n- $f_{\\mathrm{retain, SR}} = 0.90$\n- $f_{\\mathrm{entry, SR}} = 0.60$\n- $V_{\\mathrm{del, IV}} = 0.050$\n- $f_{\\mathrm{access, IV}} = 0.030$\n- $f_{\\mathrm{entry, IV}} = 0.40$\n- $\\exp(-kt) = \\frac{1}{\\sqrt{2}}$\n\nThe numerator is:\n$$V_{\\mathrm{del, SR}} \\times f_{\\mathrm{retain, SR}} \\times f_{\\mathrm{entry, SR}} = 0.10 \\times 0.90 \\times 0.60 = 0.054$$\nThe denominator is:\n$$V_{\\mathrm{del, IV}} \\times f_{\\mathrm{access, IV}} \\times f_{\\mathrm{entry, IV}} \\times \\exp(-kt) = 0.050 \\times 0.030 \\times 0.40 \\times \\frac{1}{\\sqrt{2}}$$\n$$= (0.0015) \\times 0.40 \\times \\frac{1}{\\sqrt{2}} = 0.00060 \\times \\frac{1}{\\sqrt{2}}$$\nNow, we compute the ratio $R$:\n$$R = \\frac{0.054}{0.00060 \\times \\frac{1}{\\sqrt{2}}} = \\frac{0.054}{0.00060} \\times \\sqrt{2}$$\n$$R = 90 \\times \\sqrt{2}$$\nUsing the value $\\sqrt{2} \\approx 1.41421356...$:\n$$R \\approx 90 \\times 1.41421356... = 127.27922...$$\nThe problem requires rounding the answer to three significant figures.\n$$R \\approx 127$$\nThis ratio indicates that the loading concentration for an intravitreal injection must be approximately $127$ times higher than for a subretinal injection to achieve the same therapeutic effect at the level of the photoreceptors, under the specified conditions. This reflects the significant biological barriers and clearance mechanisms that hinder intravitreal delivery to the outer retina.", "answer": "$$\\boxed{127}$$", "id": "4676270"}, {"introduction": "After successfully designing and delivering a gene therapy vector, the final question is: what fraction of target cells will actually be corrected? Because vector uptake and gene editing are stochastic processes, we must turn to probabilistic models to predict the therapeutic outcome. This practice problem [@problem_id:4676326] guides you through the process of combining a Poisson model for vector delivery with a binomial model for editing success to derive a powerful expression for the expected fraction of corrected cells, a key metric for evaluating the potential of a gene editing strategy.", "problem": "A clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene editing experiment is performed in retinal photoreceptors using adeno-associated virus (AAV) delivery to correct a pathogenic allele via homology-directed repair (HDR). Empirically, the number of AAV vector genomes per cell is well modeled by a Poisson random variable with mean $\\lambda = 1.2$. Assume that each delivered vector genome independently initiates one HDR integration attempt, and that each attempt results in a successful HDR event with probability $p = 0.01$. A cell is considered phenotypically corrected if it experiences at least one successful HDR event.\n\nStarting from the definition of the Poisson distribution and the law of total probability, derive an expression for the expected fraction of corrected cells in terms of $\\lambda$ and $p$, and then evaluate it for $\\lambda = 1.2$ and $p = 0.01$. Express your final result as a unitless decimal fraction and round your answer to four significant figures.", "solution": "The problem is valid as it is scientifically grounded, well-posed, and objective. It provides a complete set of parameters and definitions to solve a standard biostatistics problem involving compound probability distributions.\n\nThe objective is to derive an expression for the expected fraction of corrected cells, which is equivalent to the probability that a randomly-selected cell is corrected. Let this probability be denoted by $P(C)$.\n\nLet $N$ be the random variable representing the number of adeno-associated virus (AAV) vector genomes that enter a single cell. According to the problem statement, $N$ follows a Poisson distribution with mean $\\lambda$. The probability mass function (PMF) of $N$ is given by:\n$$P(N=n) = \\frac{\\lambda^n \\exp(-\\lambda)}{n!}, \\quad \\text{for } n = 0, 1, 2, \\dots$$\n\nA cell is considered phenotypically corrected if it experiences at least one successful homology-directed repair (HDR) event. Let $C$ be the event that a cell is corrected. The probability of this event, $P(C)$, can be found using the law of total probability, by conditioning on the number of vector genomes $N$:\n$$P(C) = \\sum_{n=0}^{\\infty} P(C | N=n) P(N=n)$$\nHere, $P(C | N=n)$ is the probability that a cell is corrected given that it contains exactly $n$ vector genomes.\n\nWe are given that each vector genome independently initiates an HDR attempt with a success probability of $p$. For a cell with $n$ vector genomes, this constitutes a sequence of $n$ independent Bernoulli trials. The number of successful HDR events, let's call it $S_n$, follows a binomial distribution with parameters $n$ and $p$, i.e., $S_n \\sim \\text{Binomial}(n,p)$.\n\nThe cell is corrected if $S_n \\ge 1$. It is more convenient to calculate the probability of the complementary event, i.e., that there are zero successful HDR events ($S_n=0$). The probability of zero successes in $n$ trials is:\n$$P(S_n = 0) = \\binom{n}{0} p^0 (1-p)^{n-0} = (1-p)^n$$\nTherefore, the conditional probability of a cell being corrected, given $n$ vector genomes, is:\n$$P(C | N=n) = P(S_n \\ge 1) = 1 - P(S_n=0) = 1 - (1-p)^n$$\nNote that for the case $n=0$, this expression correctly yields $P(C | N=0) = 1 - (1-p)^0 = 1 - 1 = 0$, as a cell with no vector genomes cannot be corrected.\n\nNow, we substitute the expressions for $P(N=n)$ and $P(C | N=n)$ back into the law of total probability:\n$$P(C) = \\sum_{n=0}^{\\infty} \\left[1 - (1-p)^n\\right] \\frac{\\lambda^n \\exp(-\\lambda)}{n!}$$\nWe can split this summation into two parts:\n$$P(C) = \\sum_{n=0}^{\\infty} \\frac{\\lambda^n \\exp(-\\lambda)}{n!} - \\sum_{n=0}^{\\infty} (1-p)^n \\frac{\\lambda^n \\exp(-\\lambda)}{n!}$$\nThe first term is the sum of the PMF of the Poisson distribution over its entire support, which is equal to $1$:\n$$\\sum_{n=0}^{\\infty} \\frac{\\lambda^n \\exp(-\\lambda)}{n!} = \\exp(-\\lambda) \\sum_{n=0}^{\\infty} \\frac{\\lambda^n}{n!} = \\exp(-\\lambda) \\exp(\\lambda) = 1$$\nFor the second term, we can factor out $\\exp(-\\lambda)$ and combine the terms raised to the power of $n$:\n$$\\sum_{n=0}^{\\infty} (1-p)^n \\frac{\\lambda^n \\exp(-\\lambda)}{n!} = \\exp(-\\lambda) \\sum_{n=0}^{\\infty} \\frac{[\\lambda(1-p)]^n}{n!}$$\nThe summation is the Taylor series expansion of the exponential function $\\exp(x) = \\sum_{k=0}^{\\infty} \\frac{x^k}{k!}$, with $x = \\lambda(1-p)$. Thus, the second term simplifies to:\n$$\\exp(-\\lambda) \\exp(\\lambda(1-p)) = \\exp(-\\lambda + \\lambda - \\lambda p) = \\exp(-\\lambda p)$$\nCombining the results for the two terms, we arrive at the final expression for the expected fraction of corrected cells:\n$$P(C) = 1 - \\exp(-\\lambda p)$$\nThis is the derived expression in terms of $\\lambda$ and $p$.\n\nWe are given the values $\\lambda = 1.2$ and $p = 0.01$. Substituting these into the expression:\n$$P(C) = 1 - \\exp(-(1.2)(0.01)) = 1 - \\exp(-0.012)$$\nNow, we evaluate this numerically:\n$$\\exp(-0.012) \\approx 0.988071505$$\n$$P(C) \\approx 1 - 0.988071505 = 0.011928495$$\nThe problem requires the answer to be rounded to four significant figures. The first significant figure is the first digit $1$. Counting four figures gives us $0.01192$. The fifth significant digit is $8$, which is greater than or equal to $5$, so we round up the last digit.\n$$P(C) \\approx 0.01193$$\nThis is the expected fraction of corrected cells.", "answer": "$$\\boxed{0.01193}$$", "id": "4676326"}]}